A randomised, open, parallel-group, 24-week treatment, multicentre, Phase III study to investigate the efficacy and safety of 0.5-1.0 mg daily dose of budesonide inhalation suspension in Japanese children with bronchial asthma aged 6 months-4 years
Study identifier:SD-004-0765
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, open, parallel-group, 24-week treatment, multicentre, Phase III study to investigate the efficacy and safety of 0.5-1.0 mg daily dose of budesonide inhalation suspension in Japanese children with bronchial asthma aged 6 months-4 years
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jul 2003
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
